November 3, 2025: GLP-1 Receptor Agonist Products Liability MDL Grows to 2,914 Cases The Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist products liability MDL out of the Eastern District of Pennsylvania has grown to 2,914 pending actions
From maintaining electrolyte balance to supporting gut health and energy metabolism, targeted actives can make a meaningful difference
"As with most APIs, semaglutide is following a classic trajectory-once volumes scale up, manufacturers optimise costs, and prices decline, with profitability shifting towards scale rather than margins," he said
Ellingsgaard, H
Hypoglycaemia , or low blood sugar is more common in people taking insulin or certain diabetes medications, but it can happen to those using GLP-1 injections like semaglutide (Wegovy) or tirzepatide (Mounjaro) for weight loss too
While a negative feedback loop has not been identified, the very high levels of these medications not only flood the body, but do so for extended periods, unlike endogenous GLP-1, which normally fluctuates in response to eating